GlassScriptPhysician profile
Rajiv Vyas
NPI 1093206070
$812.07
in general payments reported to CMS, 2019-2025
10 companies · $52.55 in 2025
The $52.55 reported for 2025 was less than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.23 · 2020: $43.65 · 2021: $43.69 · 2022: $186 · 2023: $315 · 2024: $90.44 · 2025: $52.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $255.22 | 2019-2023 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $123.11 | 2019-2023 | Opdivo |
| Seagen INC. | $119.84 | 2022-2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $86.45 | 2020-2024 | Imfinzi, Epanova |
| Abbvie INC. | $54.57 | 2024-2025 | |
| Gilead Sciences, INC. | $52.71 | 2022-2023 | Trodelvy |
| Incyte Corporation | $39.60 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $29.79 | 2023 | Imbruvica |
| Karyopharm Therapeutics INC. | $25.80 | 2025 | Xpovio |
| Eisai INC. | $24.98 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Vyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.